NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=140415&from=3  CLASS PER ...

NEW YORK, April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=140409&from=4CLASS PERIOD: March ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Sana Biotechnology, Inc. for the period between March 17, 2023, and November 17, 2024, due to alleged misleading statements regarding the company's financial health and product candidates [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that during the Class Period, Sana Biotechnology made false and misleading statements about its financial capacity and the potential of its product candidates [5]. - Specific allegations include that Sana was at significant risk of insufficient funds to maintain operations and that key product candidates were less promising than represented [5]. - The lawsuit asserts that the defendants overstated Sana's ability to maintain operations and advance product candidates, leading to investor damages when the truth was revealed [5]. Group 2: Participation Information - Investors who purchased Sana securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6].

SAN DIEGO, April 2, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, dia ...

NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team: https:// ...

NEW YORK, April 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.c ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: dg@securitiesclasslaw.com Phone: (646) 453-8903 CLASS PERIOD: March 17, 2023 to November 4, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Sana was at signific ...

NEW YORK, March 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SANA during the timeframe listed above, you wil ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Sana Biotechnology, Inc. due to allegations of misleading statements regarding the company's financial health and product development, with a deadline for investors to seek lead plaintiff status in a federal securities class action by May 20, 2025 [2][4]. Company Overview - Sana Biotechnology, Inc. is a publicly traded company on NASDAQ under the ticker SANA [2]. - The firm has faced significant scrutiny regarding its financial stability and product pipeline, particularly concerning its oncology and diabetes programs [4][6]. Allegations and Financial Impact - The complaint alleges that Sana misrepresented its financial capacity and the potential of its product candidates, specifically SC291, SC379, and SG299, leading to a false perception of the company's operational viability [4]. - On October 10, 2023, Sana announced a strategic shift to reduce spending on its fusogen platform and a 29% reduction in headcount, aiming to keep its 2024 operating cash burn below $200 million, which resulted in an 8.95% drop in stock price [5]. - On November 4, 2024, Sana suspended development of SC291 and SC379, reallocating resources to its type 1 diabetes program, which led to a further 9.84% decline in stock price [6]. Legal Proceedings - Investors who suffered losses exceeding $50,000 between March 17, 2023, and November 4, 2024, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class who has the largest financial interest and is typical of class members [7].

NEW YORK, March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.co ...